PURA Majority Shareholder Encouraged By Motley Fool $1 Billion Outlook For GWPH
June 13 2017 - 9:41AM
InvestorsHub NewsWire
Dallas, TX – June 13, 2017
– Puration, Inc. (USOTC:
PURA) recently became one of the first two cannabis companies
in which American Cannabis Innovations Conglomerated (ACI) acquired
a controlling interest. ACI is a private equity backed rollup
founded to combine a variety of leading young cannabis companies
with complimentary offerings and synergistic operations. ACI is
encouraged by The Motley Fool’s recent article
Which Marijuana Stock Could Be First to $1 Billion in
Annual Sales? GW Pharmaceuticals (NASDAQ: GWPH) tops
their list. ACI is optimistic that the U.S. Patented extract
process utilized by PURA rivals GWPH.
In April, this year PURA and NCM Biotech, Inc., announced that NCM
Biotech had licensed to PURA, the right to utilize NCM Biotech's
patented cannabis extraction process to produce cannabis extracts
for infusion into recreational, fitness wellness, alternative
medicine and beauty products. NCM Biotech exclusively owns U.S.
Patent No. 9,199,960, entitled "METHOD AND APPARATUS FOR PROCESSING
HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT." The
license of the process to PURA is the first and only license NCM
Biotech has executed. Since April, PURA and NCM Biotech have
been exploring opportunities to pursue pharmaceutical applications
of the NCM Biotech Patent.
"I have received doctor feedback from
more than one of our research initiatives, that extracts coming
from NCM Biotech's patented process are superior in purity and
quality to any other available cannabis extracts,"
said Frederick Ferri, CEO and Founder of NCM Biotech. "Some
feedback has specifically indicated that a number of our candidate
pharmaceutical products under development, have a greater efficacy
potential than GW
Pharmaceutical products and candidate
products.”
NCM Biotech's medical advisory team includes John N.
Gaitanis, MD., Director of Child Neurology at Tufts Medical
Center/Floating Hospital for Children; Lloyd R. Saberski,
M.D., Associate Professor of Anesthesiology and Chronic Pain
Management, Yale University, and John McMichael, Ph.D.,
President & CEO Beech Tree Labs. Research and development with
NCM Biotech's patented process has demonstrated a high potential
for bringing FDA approved pharmaceutical products to market, for
the treatment of multiple neurological disorders and cancer. The
license agreement with PURA is specifically designed to accelerate
funding for the FDA approval process, through proceeds generated by
PURA's sales of extracts for infusion into non-pharmaceutical
consumer products. Beech Tree Labs is slated to manage the FDA
approval process.
PURA is one of the first of five acquisitions in the cannabis
sector ACI has planned for the near future. ACI is seeking to
acquire early stage, undervalued businesses with intellectual
properties validated by market tests, and commercial or consumer
sales. ACI expects to accelerate the growth of acquired
assets and improve the operating efficiency of acquired assets by
improving access to investment, streamlining redundant functions
and leveraging complimentary functions.
Read The Motley Fool’s Article in
Full
Learn More About PURA:
purationinc.com
Disclaimer/Safe Harbor: This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies’ contracts, the companies’ liquidity position, the
companies’ ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure or prevent any disease.
Puration Contact:
Brian Shibley, CEO
info@purationinc.com
+1-214-937-9097
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Sep 2023 to Sep 2024